The evolving role of positron emission tomography-computed tomography in organ-preserving treatment of head and neck cancer

Madhur K. Garg, Jonathan Glanzman, Shalom Kalnicki

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The introduction of image-guided radiation therapy and intensity-modulated radiation therapy has led to unparalleled advances in achieving precise dose conformality in radiation therapy and ushered in new possibilities in organ preservation. Without the ability to meticulously delineate radiation treatment volumes, these advantages would be clinically irrelevant. Positron emission tomography (PET)/computed tomography (CT) has revolutionized the management of head and neck cancers in all areas, including diagnosis, staging, radiation treatment planning, and response evaluation. It has been shown to have a superior sensitivity for defining primary disease and both higher sensitivity and specificity for nodal disease in comparison with CT or magnetic resonance imaging during treatment planning. Thus, PET/CT frequently leads to an alteration of gross tumor volume/clinical target volume/planning target volume and often changes a patient's tumor, nodes, metastases staging. According to our data, the addition of PET to CT alone led to a modification in treatment planning in 55% of patients studied. PET/CT also helps to standardize radiation therapy between institutions and decreases interobserver variability. PET/CT is a powerful predictor of outcome after treatment. Although technical obstacles do exist and PET/CT does have small inherent inaccuracies, these can usually be overcome with careful planning and specification of setup error/margins, thereby allowing PET/CT to remain an essential and necessary tool in our fight against head and neck cancers.

Original languageEnglish (US)
Pages (from-to)320-327
Number of pages8
JournalSeminars in Nuclear Medicine
Volume42
Issue number5
DOIs
StatePublished - Sep 2012

Fingerprint

Head and Neck Neoplasms
Radiotherapy
Therapeutics
Image-Guided Radiotherapy
Radiation
Organ Preservation
Observer Variation
Positron Emission Tomography Computed Tomography
Tumor Burden
Tomography
Magnetic Resonance Imaging
Neoplasm Metastasis
Sensitivity and Specificity
Neoplasms

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

@article{a9160a1eb0f746b19601f3da0adee6e4,
title = "The evolving role of positron emission tomography-computed tomography in organ-preserving treatment of head and neck cancer",
abstract = "The introduction of image-guided radiation therapy and intensity-modulated radiation therapy has led to unparalleled advances in achieving precise dose conformality in radiation therapy and ushered in new possibilities in organ preservation. Without the ability to meticulously delineate radiation treatment volumes, these advantages would be clinically irrelevant. Positron emission tomography (PET)/computed tomography (CT) has revolutionized the management of head and neck cancers in all areas, including diagnosis, staging, radiation treatment planning, and response evaluation. It has been shown to have a superior sensitivity for defining primary disease and both higher sensitivity and specificity for nodal disease in comparison with CT or magnetic resonance imaging during treatment planning. Thus, PET/CT frequently leads to an alteration of gross tumor volume/clinical target volume/planning target volume and often changes a patient's tumor, nodes, metastases staging. According to our data, the addition of PET to CT alone led to a modification in treatment planning in 55{\%} of patients studied. PET/CT also helps to standardize radiation therapy between institutions and decreases interobserver variability. PET/CT is a powerful predictor of outcome after treatment. Although technical obstacles do exist and PET/CT does have small inherent inaccuracies, these can usually be overcome with careful planning and specification of setup error/margins, thereby allowing PET/CT to remain an essential and necessary tool in our fight against head and neck cancers.",
author = "Garg, {Madhur K.} and Jonathan Glanzman and Shalom Kalnicki",
year = "2012",
month = "9",
doi = "10.1053/j.semnuclmed.2012.04.005",
language = "English (US)",
volume = "42",
pages = "320--327",
journal = "Seminars in Nuclear Medicine",
issn = "0001-2998",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - The evolving role of positron emission tomography-computed tomography in organ-preserving treatment of head and neck cancer

AU - Garg, Madhur K.

AU - Glanzman, Jonathan

AU - Kalnicki, Shalom

PY - 2012/9

Y1 - 2012/9

N2 - The introduction of image-guided radiation therapy and intensity-modulated radiation therapy has led to unparalleled advances in achieving precise dose conformality in radiation therapy and ushered in new possibilities in organ preservation. Without the ability to meticulously delineate radiation treatment volumes, these advantages would be clinically irrelevant. Positron emission tomography (PET)/computed tomography (CT) has revolutionized the management of head and neck cancers in all areas, including diagnosis, staging, radiation treatment planning, and response evaluation. It has been shown to have a superior sensitivity for defining primary disease and both higher sensitivity and specificity for nodal disease in comparison with CT or magnetic resonance imaging during treatment planning. Thus, PET/CT frequently leads to an alteration of gross tumor volume/clinical target volume/planning target volume and often changes a patient's tumor, nodes, metastases staging. According to our data, the addition of PET to CT alone led to a modification in treatment planning in 55% of patients studied. PET/CT also helps to standardize radiation therapy between institutions and decreases interobserver variability. PET/CT is a powerful predictor of outcome after treatment. Although technical obstacles do exist and PET/CT does have small inherent inaccuracies, these can usually be overcome with careful planning and specification of setup error/margins, thereby allowing PET/CT to remain an essential and necessary tool in our fight against head and neck cancers.

AB - The introduction of image-guided radiation therapy and intensity-modulated radiation therapy has led to unparalleled advances in achieving precise dose conformality in radiation therapy and ushered in new possibilities in organ preservation. Without the ability to meticulously delineate radiation treatment volumes, these advantages would be clinically irrelevant. Positron emission tomography (PET)/computed tomography (CT) has revolutionized the management of head and neck cancers in all areas, including diagnosis, staging, radiation treatment planning, and response evaluation. It has been shown to have a superior sensitivity for defining primary disease and both higher sensitivity and specificity for nodal disease in comparison with CT or magnetic resonance imaging during treatment planning. Thus, PET/CT frequently leads to an alteration of gross tumor volume/clinical target volume/planning target volume and often changes a patient's tumor, nodes, metastases staging. According to our data, the addition of PET to CT alone led to a modification in treatment planning in 55% of patients studied. PET/CT also helps to standardize radiation therapy between institutions and decreases interobserver variability. PET/CT is a powerful predictor of outcome after treatment. Although technical obstacles do exist and PET/CT does have small inherent inaccuracies, these can usually be overcome with careful planning and specification of setup error/margins, thereby allowing PET/CT to remain an essential and necessary tool in our fight against head and neck cancers.

UR - http://www.scopus.com/inward/record.url?scp=84864399131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864399131&partnerID=8YFLogxK

U2 - 10.1053/j.semnuclmed.2012.04.005

DO - 10.1053/j.semnuclmed.2012.04.005

M3 - Article

C2 - 22840597

AN - SCOPUS:84864399131

VL - 42

SP - 320

EP - 327

JO - Seminars in Nuclear Medicine

JF - Seminars in Nuclear Medicine

SN - 0001-2998

IS - 5

ER -